Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q2 2021 · 10-Q
Revenue$0.00$0.00no prior Q2 2020 on file Net Income-$18.07M-$18.07Mno prior Q2 2020 on file EPS, diluted—
Operating Income-$17,959,000— Operating Cash Flowderived-$21,880,000—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
Free Cash Flowderived-$22,827,000— ended Jun 30, 2021 · filed Aug 6, 2021 · 37 d after period end